Company profile for Onconetix

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Onconetix, a Nasdaq-listed commercial-stage biotechnology company, is dedicated to researching, developing, and commercializing innovative solutions in the field of oncology. The company's current flagship product is Entadfi®, an FDA-approved, once-daily oral therapeutic designed for treating benign prostatic hyperplasia (BPH), a prostate disorder. In addition to its existing product, Onconetix is actively expanding its portf...
Onconetix, a Nasdaq-listed commercial-stage biotechnology company, is dedicated to researching, developing, and commercializing innovative solutions in the field of oncology. The company's current flagship product is Entadfi®, an FDA-approved, once-daily oral therapeutic designed for treating benign prostatic hyperplasia (BPH), a prostate disorder. In addition to its existing product, Onconetix is actively expanding its portfolio with a focus on therapeutics, diagnostics, and services for oncology. The company is committed to advancing solutions that benefit clinicians and patients in the oncology space.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Cincinnati, OH 45202
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/09/26/3157006/0/en/Onconetix-Announces-Financing-Through-a-12-9-Million-Private-Placement-of-Series-D-Preferred-Stock-and-Warrants-Termination-of-Merger-Agreement-with-Ocuvex-Inc-and-Settlement-of-8-.html

GLOBENEWSWIRE
26 Sep 2025

https://www.globenewswire.com/news-release/2025/09/26/3156997/0/en/Joint-Press-Release-Onconetix-and-Ocuvex-Announce-Mutual-Termination-of-Merger-Agreement.html

GLOBENEWSWIRE
26 Sep 2025

https://www.globenewswire.com/news-release/2025/09/22/3153852/0/en/Onconetix-announces-its-subsidiary-Proteomedix-licenses-manufacturing-IP-to-Immunovia-enabling-them-to-independently-produce-key-reagents-for-their-pancreatic-cancer-test-PancreaSu.html

GLOBENEWSWIRE
22 Sep 2025

https://www.globenewswire.com/news-release/2025/07/16/3116362/0/en/Onconetix-and-Ocuvex-Therapeutics-announce-execution-of-definitive-merger-agreement.html

GLOBENEWSWIRE
16 Jul 2025

https://www.globenewswire.com/news-release/2025/06/11/3097781/0/en/Onconetix-Inc-Announces-1-for-85-Reverse-Stock-Split-and-Results-of-the-Special-Meeting-of-Stockholders.html

GLOBENEWSWIRE
11 Jun 2025
Onconetix Receives Notice from Nasdaq
Onconetix Receives Notice from Nasdaq

22 May 2025

// GLOBENEWSWIRE

https://www.globenewswire.com/news-release/2025/05/22/3087138/0/en/Onconetix-Inc-Announces-Receipt-of-Additional-Notice-from-Nasdaq.html

GLOBENEWSWIRE
22 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty